The central role for SHP‐2 in oncogenic KRAS‐driven tumours has been therapeutically exploited in other contexts, with most recent data demonstrating potent synergistic antitumour effects of combined SHP‐2 and MEK inhibition in multiple cancer types 189, including genetically engineered models of KRAS‐mutant lung and pancreatic cancer 190. Here, KRAS is linked to pancreatic neoplasm.